Katalin Pungor
Neuss, NW, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
A cost of illness model to estimate the annual societal costs of X-linked retinitis pigmentosa (XLRP) in the United Kingdom (UK).
Journal: Current medical research and opinion
Published: April 11, 2026
Publisher Correction: X-Linked Retinitis Pigmentosa (XLRP): An Investigation of the Impact of XLRP on Health-Related Quality of Life of Carers in Great Britain.
Journal: Advances in therapy
Published: March 18, 2026
X-Linked Retinitis Pigmentosa (XLRP): An Investigation of the Impact of XLRP on Health-Related Quality of Life of Carers in Great Britain.
Journal: Advances in therapy
Published: October 09, 2025
The burden of X-linked retinitis pigmentosa (XLRP) on patient experience and patient-reported outcomes (PROs): findings from the EXPLORE XLRP-2 study.
Journal: Eye (London, England)
Published: May 31, 2024
Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey.
Journal: Advances in therapy
Published: April 05, 2024
Factors and their weight in reducing life expectancy in schizophrenia.
Journal: Schizophrenia research
Published: December 13, 2021
Relapse and Treatment Adherence in Patients with Schizophrenia Switching from Paliperidone Palmitate Once-Monthly to Three-Monthly Formulation: A Retrospective Health Claims Database Analysis.
Journal: Patient preference and adherence
Published: June 01, 2021
Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks' Treatment in Patients with Clinically Stable Schizophrenia.
Journal: Neuropsychiatric disease and treatment
Published: October 15, 2020
Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
Journal: Comprehensive psychiatry
Published: October 09, 2020
The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.
Journal: BMC psychiatry
Published: August 13, 2020
Stable patients with schizophrenia switched to paliperidone palmitate 3-monthly formulation in a naturalistic setting: impact of patient age and disease duration on outcomes.
Journal: Therapeutic advances in psychopharmacology
Published: April 29, 2020
Last Updated: 09/26/2026